Health ❯ Healthcare ❯ Medical Treatments

Cancer Therapies

Venetoclax and HMA CDK4/6 Inhibitors CAR-T Cell Therapy

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

Correlative findings indicate preserved immune fitness with a more stimulatory marrow environment when therapy follows one to two prior treatments.

NF1-Low ER+ Breast Cancers Identified as Likely Responders to CDK4/6 Inhibitors